CTRI/2023/06/053535招募中3 期
A Phase 3, Randomized, Double-blind, Multicenter, comparative Study to Determine the Efficacy and Safety of Cefepime-Zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male and female greater than or equal to 18 years of age. Provide a signed written informed consent prior to any study specific procedures. Meet the clinical criteria for either Complicated Urinary tract infection or Acute pyelonephritis. All females must have a negative Urine or Serum Pregnancy Test.
排除标准
- •Known or suspected disease or condition that, in the opinion of the Investigator, may confound the assessment of efficacy. Receipt of potentially-effective systemic antibacterial therapy within 48 hours prior to randomization. Rapidly progressive or terminal illness with a high risk of mortality due to any cause. Pregnant or breastfeeding women.
研究者
相似试验
进行中（未招募）
1 期
Inebilizumab efficacy and safety in IgG4 related diseaseImmunoglobulin G4-related disease (IgG4-RD)MedDRA version: 20.0Level: PTClassification code 10077271Term: Immunoglobulin G4 related diseaseSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2020-000417-33-DEViela Bio, Inc./Horizon Therapeutics Ireland DAC200
尚未招募
3 期
Phase 3 Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)10 Acute tubulo-interstitial nephritisN390 Urinary tract infection, site not specifiedAcute tubulo-interstitial nephritisUrinary tract infection, site not specifiedN390PER-021-22Wockhardt Bio AG
进行中（未招募）
1 期
Inebilizumab efficacy and safety in IgG4 related diseaseEUCTR2020-000417-33-NLViela Bio, Inc./Horizon Therapeutics Ireland DAC200
进行中（未招募）
1 期
Inebilizumab efficacy and safety in IgG4 related diseaseImmunoglobulin G4-related disease (IgG4-RD)MedDRA version: 20.0Level: PTClassification code 10077271Term: Immunoglobulin G4 related diseaseSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2020-000417-33-HUViela Bio, Inc.200
进行中（未招募）
1 期
Inebilizumab efficacy and safety in IgG4 related diseaseImmunoglobulin G4-related disease (IgG4-RD)MedDRA version: 20.0Level: PTClassification code 10077271Term: Immunoglobulin G4 related diseaseSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2020-000417-33-ITVIELABIO Inc.200